{
  "slug": "urolithin-a",
  "version": "1",
  "displayName": "Urolithin A",
  "unit": "mg",
  "doseKind": "compound",
  "ingredientGroups": [
    "Urolithin A"
  ],
  "shelfComparable": false,
  "primaryFloorId": "atlas-branded",
  "trialFloors": [
    {
      "id": "atlas-branded",
      "label": "ATLAS trial, branded Mitopure",
      "presetLabel": "ATLAS 500 mg",
      "amount": 500,
      "amountMax": 1000,
      "frequency": "daily",
      "horizon": "4 months",
      "evidenceLevel": "limited",
      "pmids": [
        "35584623"
      ],
      "note": "Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.",
      "effectDirection": "secondary-only",
      "funding": "industry",
      "funder": "Amprocell (ATLAS sponsor)"
    },
    {
      "id": "older-adults-1g",
      "label": "Older adults, 1000 mg",
      "presetLabel": "Liu 2022",
      "amount": 1000,
      "frequency": "daily",
      "horizon": "4 months",
      "evidenceLevel": "limited",
      "palette": "research",
      "pmids": [
        "35050355"
      ],
      "n": 66,
      "note": "Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated.",
      "effectDirection": "null",
      "funding": "not-stated"
    },
    {
      "id": "safety-biology",
      "label": "Safety and mitochondrial gene signature",
      "presetLabel": "Andreux 2019",
      "amount": 500,
      "amountMax": 1000,
      "frequency": "daily",
      "horizon": "4 weeks",
      "evidenceLevel": "limited",
      "palette": "research",
      "pmids": [
        "32694802"
      ],
      "n": 60,
      "note": "Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers \"does oral urolithin A do anything in tissue\", not \"will I be stronger\".",
      "effectDirection": "null",
      "funding": "not-stated"
    },
    {
      "id": "endothelial-1g",
      "label": "Endothelial function trial (1000 mg)",
      "presetLabel": "da Costa Pinaffi-Langley 2026",
      "amount": 1000,
      "frequency": "daily",
      "horizon": "4 weeks",
      "evidenceLevel": "limited",
      "palette": "research",
      "pmids": [
        "42853569"
      ],
      "n": 50,
      "note": "Double-blind placebo-controlled single-site trial in adults 40-64 with obesity; the primary endpoint, brachial artery flow-mediated dilation, did not separate from placebo, nor did secondary peripheral endothelial measures. Exploratory cerebrovascular hemodynamics moved in the urolithin group. Cited by our urolithin A vs NMN guide.",
      "effectDirection": "null",
      "funding": "independent"
    }
  ],
  "guideSlugs": [
    "urolithin-a-vs-nmn"
  ],
  "guideUrls": [
    "https://supplementbrief.com/urolithin-a-vs-nmn/"
  ],
  "shelf": null,
  "updatedDate": "2026-10-11",
  "dosePageUrl": "https://supplementbrief.com/dose/urolithin-a/",
  "jsonUrl": "https://supplementbrief.com/data/v1/doses/urolithin-a.json",
  "htmlUrl": "https://supplementbrief.com/data/v1/doses/urolithin-a/"
}
